Form 4: Vaxcyte SVP Finance Elvia Cowan Reports Equity Awards

Vaxcyte's SVP of Finance, Elvia Cowan, reported the acquisition of restricted stock units and stock options as part of her compensation.

Summary

• Elvia Cowan, SVP of Finance at Vaxcyte, Inc. (PCVX), reported changes in her beneficial ownership of company securities.
• Acquired 2,810 shares of Common Stock underlying Restricted Stock Units (RSUs) on September 7, 2025, with a grant price of $0.
• Acquired 9,743 Stock Options (right to buy) on August 29, 2025, with an exercise price of $30.79 per share.
• The RSUs will vest as to 25% of the shares on March 7, 2026, and 12.5% every six months thereafter, contingent on continuous service.
• The Stock Options will vest 1/48 of the shares on September 29, 2025, and 1/48 monthly thereafter, contingent on continuous service.
• Following these transactions, Ms. Cowan beneficially owns 27,205 shares of Common Stock and 9,743 Stock Options.
• The reported Common Stock holdings include 289 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation grants to a senior executive, which is a neutral to slightly positive event as it aligns management incentives with shareholder interests. It does not indicate any significant operational or financial changes.

Positives

• The grant of restricted stock units and stock options aligns the interests of the SVP of Finance with those of shareholders, promoting long-term value creation.
• Equity compensation is a standard practice for retaining key executives and incentivizing performance.

Future Outlook

The filing details future vesting schedules for the granted restricted stock units and stock options, contingent on the reporting person's continuous service with Vaxcyte, Inc. The RSUs will begin vesting on March 7, 2026, and the stock options on September 29, 2025.

Industry Context

The grant of equity awards, such as restricted stock units and stock options, is a common and standard practice in the biotechnology and pharmaceutical industries to compensate, retain, and incentivize key executives. This aligns executive performance with shareholder value creation over the long term.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed in the biotechnology sector, similar to companies like Moderna or BioNTech for their senior leadership.
• The use of performance-based or time-based vesting, as seen with the continuous service requirement, is a standard mechanism to ensure executive retention and alignment with company goals, mirroring practices at peer companies in the biopharmaceutical space.

Stakeholder Impact

• Shareholders: The equity awards align the interests of a key executive with shareholders, potentially fostering long-term value creation.
• Employees: The compensation structure for senior management can set a precedent or reflect the company's overall approach to employee incentives.

Next Steps

• Continued vesting of Restricted Stock Units, with the first tranche on March 7, 2026.
• Continued vesting of Stock Options, with the first tranche on September 29, 2025.

Key Dates

Recommendation

This Form 4 reports routine equity compensation grants to an executive, which is a standard practice for aligning management incentives with shareholder interests. It does not provide new information that would significantly alter the investment thesis for Vaxcyte, Inc., thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Vaxcyte, PCVX, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Executive Compensation, Biotechnology